Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

Virtual event on Friday, March 1, 2024 at 10:00 AM ET

Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of University of Glasgow, and David Cornblath, MD, Professor Emeritus of Johns Hopkins University School of Medicine

BRISBANE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced it will host a virtual R&D Day on Friday, March 1, 2024 at 10:00 AM ET. To register, click here.

The event will feature GBS experts who will provide an overview of Guillain-Barré syndrome (GBS), the most common cause of acute neuromuscular paralysis:

• Lisa Butler, Executive Director, GBS|CIDP Foundation International
• Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology, University of Glasgow
• David Cornblath, MD, Professor Emeritus of Neurology, Johns Hopkins University School of Medicine
  

Presentations from GBS experts and Annexon management will highlight:

• Current treatment landscape and opportunities for new therapies from the patient and clinician perspective
• Targeting C1q in GBS with ANX005, Annexon's investigational monoclonal antibody designed to inhibit C1q and stop classical complement pathway activation before it starts
• Annexon's pivotal Phase 3 trial expected to read out in the second quarter of this year
• The GBS market opportunity and Annexon's commercial approach

A live question and answer will follow formal presentations.

About Lisa Butler
Lisa Butler first joined the GBS|CIDP Foundation community as the Parent Liaison for parents with children diagnosed with GBS, following her son Stuart’s diagnosis of GBS in 2002. In 2013 Lisa was appointed Executive Director of the Foundation and has since led their mission to ensure that no one faces these rare conditions alone. Lisa brings a wide breadth of experience in managing the Foundation’s strategic relationships, volunteers, patient advocacy programs, and legislative efforts affecting the lives of GBS|CIDP patients. She was recognized by Patient Services, Inc. (PSI) with the 2016 Extraordinary Support Award. Lisa was elected to the board of directors for the National Health Council in 2023 and sits on the finance and membership committees. She is also a member of the board for the Late-Onset Neuromuscular Consortium.